Eli Lilly and Co officer, Zakrowski Donald A, is set to sell 750 shares of the company's common stock on 08/26/2024, with an aggregate market value of $712,500. The shares to be sold were acquired through the vesting of performance share awards, part of the issuer's equity compensation plan, on 02/09/2022 and 02/10/2023, amounting to 346 and 404 shares respectively. This planned sale follows a similar transaction where Zakrowski sold 750 shares for a total gross proceed of $614,602.5 in the past three months.

Eli Lilly and Co officer, Zakrowski Donald A, is set to sell 750 shares of the company's common stock on 08/26/2024, with an aggregate market value of $712,500. The shares to be sold were acquired through the vesting of performance share awards, part of the issuer's equity compensation plan, on 02/09/2022 and 02/10/2023, amounting to 346 and 404 shares respectively. This planned sale follows a similar transaction where Zakrowski sold 750 shares for a total gross proceed of $614,602.5 in the past three months.